TL;DR
Get health and wellness essentials delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The phase III SYNCHRONIZE-2 trial found that adults with type 2 diabetes and obesity taking survodutide lost more weight and had greater HbA1c reductions than participants receiving placebo over 76 weeks. Gastrointestinal side effects were common, and treatment discontinuation was substantially higher in both survodutide groups.
The investigational GIP/GLP-1 drug survodutide produced greater weight loss and reductions in blood sugar than placebo among adults with type 2 diabetes and obesity in the phase III SYNCHRONIZE-2 trial, but gastrointestinal side effects led many participants to stop treatment. Results presented at the European Association for the Study of Diabetes meeting in Milan and published in the New England Journal of Medicine point to potential metabolic benefits, with tolerability remaining a major limitation.
At week 76, participants assigned to weekly survodutide lost an average of 8.2% of body weight with the 3.6-mg dose and 9.8% with the 6-mg dose. The placebo group lost an average of 3.9%. At least 5% weight loss — the trial’s threshold for clinically significant weight reduction — was reached by 57.6% and 64.5% of the two survodutide groups, compared with 35.1% of placebo recipients. The reported comparisons with placebo were statistically significant.
Average HbA1c, a measure of blood sugar over time, fell by 0.9 percentage points in the 3.6-mg group and 0.8 points in the 6-mg group, compared with 0.2 points with placebo. Mean HbA1c at the start of the study was 7.4%. Sean Wharton, a physician at Wharton Medical Clinic Weight and Diabetes Management in Hamilton, Ontario, presented the findings. He also said survodutide was associated with improvements in systolic blood pressure, waist circumference and blood lipid measures.
Side effects affected the treatment’s practical performance. Gastrointestinal adverse events occurred in 73% to 78% of participants taking survodutide, versus 38.6% of those taking placebo. Most were described as mild to moderate and temporary, but gastrointestinal events led 18% of participants in each survodutide group to discontinue the trial regimen, compared with 1.2% in the placebo group. Discontinuation because of any adverse event was 26% in both drug groups and 9% with placebo.
Benefits Must Be Weighed Against Dropouts
The results show that survodutide can improve weight and blood sugar measures in this study population, but the high rate of treatment discontinuation complicates the assessment of its benefits. A medicine’s results in a trial do not tell the full story if a substantial share of patients cannot or do not continue taking it. The gap between gastrointestinal-related discontinuation on survodutide and placebo is therefore central to interpreting the findings.
Wharton and colleagues described the weight loss in the higher-dose group as a magnitude associated with cardiovascular benefits and fewer metabolic and mechanical complications, as well as improved quality of life. That is the researchers’ interpretation of the weight-loss level, not evidence from this trial that survodutide reduced cardiovascular events or complications. The available results establish changes in weight and other measured risk factors; they do not establish those longer-term outcomes.
Comparisons with other drugs also need care. The report cited larger weight-loss or HbA1c reductions in studies of high-dose semaglutide, tirzepatide and investigational retatrutide. Those figures come from separate trials, with potentially different participants and study designs, and do not amount to a direct head-to-head comparison. The findings do, however, make tolerability an important point of comparison as survodutide development continues.
Gastrointestinal side effect management supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How SYNCHRONIZE-2 Was Designed
The multinational, double-blind trial enrolled 752 participants from November 2023 through March 2026: 250 received the 3.6-mg dose, 251 received 6 mg, and 251 received placebo. Participants had type 2 diabetes and a body mass index of at least 27. Their average age was 55.7 years, and average BMI was 36.5. Treatment was given as a once-weekly injection.
The study population has limits that matter when applying the findings more broadly. People taking insulin were excluded, and most participants had relatively well-controlled blood sugar while using oral glucose-lowering medicines. The results may not reflect outcomes for people with more difficult-to-control diabetes or those using insulin. The researchers also reported less weight loss than the maximum 13% reported in SYNCHRONIZE-1, an earlier trial that excluded people with diabetes; the populations and trials should not be treated as interchangeable.
Survodutide acts on GIP and GLP-1 pathways and is being studied for metabolic conditions. In comments reported from the meeting, Andreas Birkenfeld of University Hospital Tübingen said the trial showed no additional safety signal beyond what was already known, while also pointing to the higher gastrointestinal-related dropout rate. He suggested the dose-escalation approach could be a factor: the 6-mg regimen used a six-step increase over 24 weeks.
“It’s reassuring we see no additional safety signal beyond what we already know.”
— Andreas Birkenfeld, MD, PhD, of University Hospital Tübingen, speaking at the EASD meeting
Tolerability and Patient Reach
The trial results do not establish whether a revised dose-escalation schedule will reduce nausea or other gastrointestinal events, or prevent participants from stopping treatment. Birkenfeld suggested the six-step, 24-week escalation to the 6-mg dose might help explain the dropout rate, but that explanation remains a possibility rather than a demonstrated cause.
It is also unclear how well the findings apply to people with type 2 diabetes who use insulin or have less controlled blood sugar, because insulin users were excluded and most participants entered the trial with relatively well-controlled glycemic levels. The reported results do not show whether survodutide prevents heart attacks, strokes or other cardiovascular outcomes. The trial’s measured changes in weight, HbA1c and risk factors should not be mistaken for proof of such benefits.
The cited efficacy comparisons with other medicines are not direct comparisons within SYNCHRONIZE-2. Differences in trial design and participant groups limit what can be concluded about which treatment performs better or is easier to tolerate. Further results are needed to clarify how survodutide’s benefits and side effects compare under different dosing approaches.
Dose Strategies and Outcomes Ahead
Boehringer Ingelheim says upcoming trials will use more flexible, patient-centered dose titration to try to improve tolerability. Those studies will need to show whether changing the pace or steps of dose increases reduces gastrointestinal events and treatment discontinuations while preserving the observed effects on weight and blood sugar.
The developer is also evaluating survodutide for other metabolic conditions. According to the report, data from a cardiovascular outcomes trial are expected later this year. That evidence may help address whether changes in weight and cardiometabolic measures translate into cardiovascular outcomes, a question SYNCHRONIZE-2 was not designed to answer.
For now, the phase III findings provide evidence of a treatment effect compared with placebo in the enrolled population, alongside a clear tolerability concern. Results from future trials and further safety reporting will help determine how the drug’s dosing, effectiveness and ability to keep patients on treatment compare across broader groups.
Key Questions
What did SYNCHRONIZE-2 find?
At week 76, average weight loss was 8.2% with 3.6 mg and 9.8% with 6 mg of survodutide, compared with 3.9% with placebo. HbA1c also fell more in both survodutide groups than in the placebo group.
What were the main side effects reported?
Gastrointestinal adverse events were reported in 73% to 78% of participants taking survodutide, compared with 38.6% taking placebo. Most events were described as mild to moderate and temporary, but gastrointestinal problems led 18% of participants in each drug group to discontinue the trial regimen.
Does this trial prove survodutide prevents heart disease?
No. The reported trial results cover weight, HbA1c and other cardiometabolic measures, not proof that the drug prevents heart attacks or other cardiovascular events. A separate cardiovascular outcomes trial is ongoing, with data expected later this year according to the report.
Can the results be applied to everyone with type 2 diabetes?
Not directly. SYNCHRONIZE-2 excluded people taking insulin, and most participants had relatively well-controlled blood sugar while using oral medicines. The findings may not represent people with more difficult-to-control diabetes or those treated with insulin.
What is planned to address the dropout rate?
Boehringer Ingelheim says upcoming trials will test more flexible, patient-centered titration strategies. Whether those changes will lower gastrointestinal side effects and discontinuation rates remains to be seen.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
